CRISPR Therapeutics
CRSP
CRSP
402 hedge funds and large institutions have $2.54B invested in CRISPR Therapeutics in 2024 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 114 increasing their positions, 121 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
10% less capital invested
Capital invested by funds: $2.81B → $2.54B (-$270M)
11% less call options, than puts
Call options by funds: $81.6M | Put options by funds: $91.6M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
402
Holding in Top 10
4
Calls
$81.6M
Puts
$91.6M
Top Buyers
| 1 | +$69.7M | |
| 2 | +$69.6M | |
| 3 | +$61.9M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$50.7M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$38.6M |
Top Sellers
| 1 | -$28.7M | |
| 2 | -$23.7M | |
| 3 | -$21M | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.1M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$10.5M |